AA
ARCT icon

ALPS Advisors’s Arcturus Therapeutics ARCT Stock Holding History

ALPS Advisors’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$194K Buy
28,845
+5,705
+25% +$45K ﹤0.01% 1164
2026
Q1 		$179K Sell
23,140
-185
-0.8% -$1.35K ﹤0.01% 1030
2025
Q4 		$143K Buy
23,325
+10,224
+78% +$110K ﹤0.01% 1002
2025
Q3 		$241K Sell
13,101
-1,518
-10% -$24.4K ﹤0.01% 1003
2025
Q2 		$190K Sell
14,619
-5,330
-27% -$63K ﹤0.01% 1009
2025
Q1 		$211K Sell
19,949
-1,952
-9% -$31K ﹤0.01% 959
2024
Q4 		$372K Buy
21,901
+63
+0.3% +$1.19K ﹤0.01% 741
2024
Q3 		$507K Sell
21,838
-8,277
-27% -$177K ﹤0.01% 608
2024
Q2 		$733K Buy
30,115
+2,102
+8% +$63.7K 0.01% 520
2024
Q1 		$946K Sell
28,013
-207
-0.7% -$7.33K 0.01% 502
2023
Q4 		$890K Sell
28,220
-2,103
-7% -$50K 0.01% 510
2023
Q3 		$775K Buy
30,323
+10,799
+55% +$333K 0.01% 528
2023
Q2 		$560K Buy
+19,524
New +$531K ﹤0.01% 592
2022
Q4 		– Sell
-14,481
Closed -$215K – 1027
2022
Q3 		$215K Sell
14,481
-1,196
-8% -$20.1K ﹤0.01% 997
2022
Q2 		$247K Sell
15,677
-11,425
-42% -$224K ﹤0.01% 950
2022
Q1 		$731K Sell
27,102
-3,403
-11% -$86.8K 0.01% 343
2021
Q4 		$1.13M Sell
30,505
-1,754
-5% -$71.5K 0.01% 346
2021
Q3 		$1.54M Sell
32,259
-2,406
-7% -$108K 0.01% 346
2021
Q2 		$1.17M Buy
+34,665
New +$1.17M 0.01% 385
2020
Q4 		– Sell
-31,101
Closed -$1.33M – 839
2020
Q3 		$1.33M Buy
31,101
+3,148
+11% +$156K 0.02% 292
2020
Q2 		$1.31M Buy
+27,953
New +$963K 0.02% 275

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

ALPS Advisors's ARCT Position: Q2 2026 in Review

ALPS Advisors increased its Arcturus Therapeutics (ARCT) stake by 25% in Q2 2026, buying an estimated $45K and bringing the position to 28,845 shares worth $194K. The position accounts for ﹤0.01% of the portfolio, ranked #1164.

ALPS Advisors first reported a position in ARCT in Q2 2020 and has held it in 21 quarters since. The position peaked at $1.54M in Q3 2021. 136 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

  • ALPS Advisors held 28,845 shares of Arcturus Therapeutics worth $194K as of Q2 2026.
  • ALPS Advisors bought 5,705 Arcturus Therapeutics shares in Q2 2026, an estimated $45K.
  • Arcturus Therapeutics made up ﹤0.01% of ALPS Advisors's portfolio in Q2 2026, its #1164 holding.
  • ALPS Advisors first reported a position in Arcturus Therapeutics in Q2 2020 and has held it in 21 quarters since.
  • ALPS Advisors's Arcturus Therapeutics position peaked at $1.54M in Q3 2021.
  • 136 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.